Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | RAD51C R193* |
| Gene Variant Detail | |
| Relevant Treatment Approaches | Olaparib |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| RAD51C R193* | ovarian carcinoma | predicted - sensitive | Rucaparib | Case Reports/Case Series | Actionable | In a clinical case study, an ovarian carcinoma patient harboring a RAD51C R193* germline mutation demonstrated a partial response when treated with Rubraca (rucaparib) (PMID: 28588062). | 28588062 | |
| RAD51C R193* | ovarian cancer | sensitive | Niraparib + TNG348 | Preclinical - Pdx | Actionable | In a preclinical study, treatment with the combination of TNG348 and Zejula (niraparib) resulted in greater inhibition of tumor growth than either agent alone in a patient-derived xenograft (PDX) model of ovarian cancer harboring RAD51C R193* (PMID: 39886906). | 39886906 |